Emergent signs $174 million deal to make AstraZeneca’s potential COVID-19 vax

Emergent BioSolutions Inc said on Monday it signed a $174 million (135 million pounds) agreement with AstraZeneca to develop and manufacture the British drugmaker’s COVID-19 vaccine candidate.

AstraZeneca in June picked Emergent to help produce the 300 million doses of its potential COVID-19 vaccine pledged to the United States.

https://www.marketscreener.com/ASTRAZENECA-PLC-4000930/news/Emergent-signs-174-million-deal-to-make-AstraZeneca-s-potential-COVID-19-vaccine-30995522/